ARCA biopharma, Inc. (ABIO:NASDAQ) Investor Relations Material

Overview

ARCA Biopharma Inc., a clinical development stage biopharmaceutical company, is actively engaged in the development and commercialization of genetically targeted therapies for cardiovascular diseases. With its flagship product Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist, the company has successfully completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. In addition to Gencaro, ARCA Biopharma Inc. is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is currently in Phase IIb clinical trial for the treatment of COVID-19. A proud recipient of a collaboration agreement with LabCorp, ARCA Biopharma Inc. is developing a genetic test for the GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

Annual Reports

Frequently Asked Questions

What is ARCA biopharma, Inc.'s ticker?

ARCA biopharma, Inc.'s ticker is ABIO

What exchange is ARCA biopharma, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are ARCA biopharma, Inc.'s headquarters?

They are based in Westminster, Colorado

How many employees does ARCA biopharma, Inc. have?

There are 11-50 employees working at ARCA biopharma, Inc.

What is ARCA biopharma, Inc.'s website?

It is https://arcabio.com/

What type of sector is ARCA biopharma, Inc.?

ARCA biopharma, Inc. is in the Healthcare sector

What type of industry is ARCA biopharma, Inc.?

ARCA biopharma, Inc. is in the Biotechnology industry

Who are ARCA biopharma, Inc.'s peers and competitors?

The following five companies are ARCA biopharma, Inc.'s industry peers:

- Mereo BioPharma Group plc

- NantKwest, Inc.

- Catabasis Pharmaceuticals, Inc.

- PureTech Health

- Intec Pharma